Table 1.
Baseline characteristics of patients randomized to treatment (safety analysis set)
| Characteristic | OLM/AML 40/10 mg (n = 244) | PER/AML 8/10 mg (n = 241) | Total (n = 485) |
|---|---|---|---|
| Mean age, years | 60.9 (9.21) | 60.8 (9.38) | 60.9 (9.28) |
| Male | 176 (72.1) | 180 (74.7) | 356 (73.4) |
| Caucasian | 244 (100.0) | 240 (99.6) | 484 (99.8) |
| Body weight, kg | 86.1 (15.12) | 87.2 (15.16) | 86.7 (15.14) |
| Body mass index, kg/m2 | 31.1 (4.14) | 31.5 (4.38) | 31.3 (4.26) |
| Males aged >55 years/females aged >65 years | 160 (65.6) | 154 (63.9) | 314 (64.7) |
| Smoker | 47 (19.3) | 76 (31.5) | 123 (25.4) |
| Dyslipidemia | 225 (92.2) | 217 (90.0) | 442 (91.1) |
| Type 2 diabetes | 111 (45.5) | 122 (50.6) | 233 (48.0) |
| Abnormal glucose tolerance test | 47 (19.3) | 52 (21.6) | 99 (20.4) |
| Abdominal obesity | 213 (87.3) | 208 (86.3) | 421 (86.8) |
| Family history of premature CV disease | 25 (10.2) | 26 (10.8) | 51 (10.5) |
| Cerebrovascular disease | 24 (9.8) | 15 (6.2) | 39 (8.0) |
| Heart disease | 8 (3.3) | 12 (5.0) | 20 (4.1) |
| Advanced retinopathy | 2 (0.8) | 7 (2.9) | 9 (1.9) |
| Atherosclerosis | 10 (4.1) | 7 (2.9) | 17 (3.5) |
| Renal disease | 66 (27.0) | 67 (27.8) | 133 (27.4) |
Continuous variables are mean (SD), categorical variables are number of patients (%)
AML amlodipine, CV cardiovascular, OLM olmesartan, PER perindopril